Cambrex Co. (NYSE:CBM) CEO Sells $20,828,887.94 in Stock

Cambrex Co. (NYSE:CBM) CEO Steven M. Klosk sold 347,206 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $59.99, for a total value of $20,828,887.94.

CBM opened at $59.99 on Friday. The company’s 50 day moving average is $59.80 and its 200 day moving average is $53.29. The company has a current ratio of 2.37, a quick ratio of 1.70 and a debt-to-equity ratio of 0.76. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 21.66 and a beta of 2.14. Cambrex Co. has a 12-month low of $33.80 and a 12-month high of $60.29.

Cambrex (NYSE:CBM) last announced its earnings results on Thursday, October 31st. The biotechnology company reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.01. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. The business had revenue of $148.56 million during the quarter.

Hedge funds have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in shares of Cambrex in the 1st quarter worth $30,000. Quantamental Technologies LLC bought a new position in Cambrex in the 2nd quarter worth $100,000. Tower Research Capital LLC TRC lifted its position in Cambrex by 67.7% during the second quarter. Tower Research Capital LLC TRC now owns 2,188 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 883 shares in the last quarter. Magnus Financial Group LLC purchased a new position in Cambrex during the second quarter valued at $215,000. Finally, Panagora Asset Management Inc. lifted its position in Cambrex by 205.9% during the second quarter. Panagora Asset Management Inc. now owns 4,894 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 3,294 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

CBM has been the topic of a number of research reports. Craig Hallum downgraded Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a research note on Monday, August 12th. ValuEngine cut Cambrex from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Finally, Zacks Investment Research downgraded Cambrex from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $54.83.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

See Also: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.